Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
|Videos|January 21, 2017
CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC
Author(s)Hans-Joachim Schmoll, MD, PhD
This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
Advertisement
The CHARTA trial tested FOLFOX plus bevacizumab with or without irinotecan in patients with metastatic colorectal cancer.
In this video, Hans-Joachim Schmoll, MD, PhD, of the Martin Luther University Halle-Wittenberg in Halle, Germany, discusses results of the trial, covering the survival outcomes, subgroup analyses, and quality-of-life data.
The results of CHARTA (
Advertisement
Related to this article
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
Futibatinib, pemigatinib, and lirafugratinib showed similar response rates and progression-free survival at first FGFR inhibitor exposure in biliary tract cancers with FGFR alterations.
A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
2
Closing the Gaps in Precision Oncology for Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5